Mossman Associates
Private Company
Funding information not available
Overview
Mossman Associates is a privately held, commercial-stage company with a dual focus on diagnostic testing and therapeutic technology. Its flagship diagnostic, NicCheck I, holds a unique market position as the only FDA-cleared, CLIA-waived rapid nicotine test. Its therapeutic offering, the BioSound Therapy System, is a multi-sensory device integrating biofeedback, sound therapy, and guided imagery, targeted at addiction treatment centers, mental health clinics, and first responders. The company leverages decades of industry experience from its founder to commercialize these niche products.
Technology Platform
Two distinct platforms: 1) NicCheck I - CLIA-waived, semi-quantitative lateral flow immunoassay for nicotine/metabolites. 2) BioSound Therapy System - integrated multi-sensory device combining a vibrational platform, audio/visual delivery, biofeedback, sound frequency therapy, and guided imagery.
Opportunities
Risk Factors
Competitive Landscape
For NicCheck I, competition includes laboratory-based LC-MS/MS tests (more accurate but slower/expensive) and other rapid tests without CLIA-waived status. In therapeutic devices, the BioSound System competes with a wide range of meditation apps, biofeedback devices, and other multi-sensory relaxation technologies, though its integrated hardware/software approach targets a specific professional clientele.